Long-term renal outcomes of APRT deficiency presenting in childhood.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
AuthorsRunolfsdottir, Hrafnhildur Linnet
Agustsdottir, Inger MSch
Indridason, Olafur S
Edvardsson, Vidar O
MetadataShow full item record
CitationLong-term renal outcomes of APRT deficiency presenting in childhood. 2019, 34(3): 435-442 Pediatr Nephrol
AbstractAdenine phosphoribosyltransferase (APRT) deficiency is a hereditary purine metabolism disorder that causes kidney stones and chronic kidney disease (CKD). The purpose of this study was to examine the course of APRT deficiency in patients who presented in childhood. The disease course of 21 (35%) patients in the APRT Deficiency Registry of the Rare Kidney Stone Consortium, who presented with manifestations of APRT deficiency and/or were diagnosed with the disorder before the age of 18 years, was studied. The effect of pharmacotherapy on renal manifestations and outcomes was thoroughly assessed. Fourteen children were placed on allopurinol, 100 (25-200) mg/day, at the age of 2.6 (0.6-16.5) years. Six of these patients had experienced kidney stone events and three had developed acute kidney injury (AKI) prior to allopurinol treatment. During 18.9 (1.7-31.5) years of pharmacotherapy, stones occurred in two patients and AKI in three. Six adult patients started allopurinol treatment, 200 (100-300) mg/day, at age 29.8 (20.5-42.4) years. Five of these patients had experienced 28 stone episodes and AKI had occurred in two. Stone recurrence occurred in four patients and AKI in two during 11.2 (4.2-19.6) years of allopurinol therapy. Lack of adherence and insufficient dosing contributed to stone recurrence and AKI during pharmacotherapy. At latest follow-up, estimated glomerular filtration rate (eGFR) was 114 (70-163) and 62 (10-103) mL/min/1.73 m Timely diagnosis and treatment of APRT deficiency decreases renal complications and preserves kidney function.
DescriptionTo access publisher's full text version of this article click on the hyperlink below
- Kidney Disease in Adenine Phosphoribosyltransferase Deficiency.
- Authors: Runolfsdottir HL, Palsson R, Agustsdottir IM, Indridason OS, Edvardsson VO
- Issue date: 2016 Mar
- Chronic tubulointerstitial kidney disease in untreated adenine phosphoribosyl transferase (APRT) deficiency: A case report .
- Authors: Cochran B, Kovačíková T, Hodaňová K, Živná M, Hnízda A, Niehaus AG, Bonnecaze A, Balasubraminiam G, Ceballos-Picot I, Hawfield A, Kidd K, Kmoch S, Bleyer AJ
- Issue date: 2018 Oct
- Adenine phosphoribosyltransferase deficiency.
- Authors: Bollée G, Harambat J, Bensman A, Knebelmann B, Daudon M, Ceballos-Picot I
- Issue date: 2012 Sep
- Adenine phosphoribosyltransferase deficiency and 2, 8-dihydroxyadenine renal stones: A preventable cause of pediatric renal stones and kidney disease.
- Authors: Parikh MD, Konnur A, Gang S
- Issue date: 2019 May-Jun
- Comparison of the effect of allopurinol and febuxostat on urinary 2,8-dihydroxyadenine excretion in patients with Adenine phosphoribosyltransferase deficiency (APRTd): A clinical trial.
- Authors: Edvardsson VO, Runolfsdottir HL, Thorsteinsdottir UA, Sch Agustsdottir IM, Oddsdottir GS, Eiriksson F, Goldfarb DS, Thorsteinsdottir M, Palsson R
- Issue date: 2018 Feb